RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.
about
Treatment of Retinoblastoma: The Role of External Beam RadiotherapyRB1: a prototype tumor suppressor and an enigmaRetinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventionsAPC/C and retinoblastoma interaction: cross-talk of retinoblastoma protein with the ubiquitin proteasome pathwayProteomic analysis of pRb loss highlights a signature of decreased mitochondrial oxidative phosphorylationTherapeutic options for HER-2 positive breast cancer: Perspectives and future directionsRB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.Clinical correlation of extensive-stage small-cell lung cancer genomics.Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.pRb controls estrogen receptor alpha protein stability and activity.RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1.Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers.A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas.RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy.p16 Methylation is associated with chemosensitivity to fluorouracil in patients with advanced gastric cancer.Mutation of the retinoblastoma tumor suppressor gene sensitizes cancers to mitotic inhibitor induced cell death.Defining a new vision for the retinoblastoma gene: report from the 3rd International Rb MeetingEffects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines.Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer.Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.Digital gene expression profiling analysis and its application in the identification of genes associated with improved response to neoadjuvant chemotherapy in breast cancer.Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer
P2860
Q26786290-449673A4-AB8C-4884-8955-EE3955080DF2Q26866393-22724339-B8A5-4987-A027-C451BAE5A943Q27022834-0E5560BB-47BB-4606-845D-BB775B309002Q28072560-79FF0D91-051D-4D3E-B57A-BA95BD5E96EDQ28607552-7F9A32E7-4B90-48C9-AC5E-B195D9EE728EQ34023704-FE5B5016-55FC-4E67-BFF8-A824612ACEFEQ35050328-1BB2C995-1F2F-4F99-A31C-5EB181A1B23BQ35157633-CDCB2E1A-49B7-4B89-A861-653BF4C3C25FQ36716670-E3244542-7DC1-4B38-861B-17A25C6F4080Q37012053-684E02E2-79B0-4589-9036-54096B650397Q37132236-9FE54113-DD43-4831-9731-9ACD37E91AB1Q37507931-ACB6D682-DF75-4842-B3DD-15E5F0C783C6Q37618855-DBCC91C7-C062-482E-8AED-14654518AE60Q37708740-88E7FA1B-53FF-49F7-B796-95331C7662C2Q37721452-BDAC573F-59AE-48C9-9EDC-EB92270C3702Q38087850-80141A3A-F540-47D3-B64C-972D2098D23DQ38395549-B07E52E0-4894-4763-AD52-D2E6E3AE5FE5Q38544737-9536BBA9-3776-4CAE-97F6-D6207E040D40Q39194676-C4A9881D-59C0-4F9E-850D-20FD4A6462D8Q41891569-5BC77AA9-16E1-420C-9F80-24D81B7500AAQ42141064-630901BF-7609-4C5E-8641-1C3271F95854Q42253633-3C05CFF4-6AC1-4A36-ADF0-B5C77DB6EC74Q49547342-B81A3293-9C37-4930-AA7B-7F74AE53155BQ54324226-E7EE84C5-B7F1-4959-A13B-146DB21E81F6Q54977441-56D840C9-4840-4637-B18B-382CED4AFDFDQ55403730-E4C3736C-7745-4560-9ECE-825FB2F2D4FCQ58623046-E6E47726-5D48-4A5C-804B-0E9D8CAFF14D
P2860
RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
RB-pathway disruption is assoc ...... chemotherapy in breast cancer.
@ast
RB-pathway disruption is assoc ...... chemotherapy in breast cancer.
@en
type
label
RB-pathway disruption is assoc ...... chemotherapy in breast cancer.
@ast
RB-pathway disruption is assoc ...... chemotherapy in breast cancer.
@en
prefLabel
RB-pathway disruption is assoc ...... chemotherapy in breast cancer.
@ast
RB-pathway disruption is assoc ...... chemotherapy in breast cancer.
@en
P2093
P2860
P1476
RB-pathway disruption is assoc ...... chemotherapy in breast cancer.
@en
P2093
Adam Ertel
Agnieszka K Witkiewicz
Erik S Knudsen
Gordon Schwartz
Jeanne McFalls
Matias E Valsecchi
P2860
P304
P356
10.1158/1078-0432.CCR-12-0903
P407
P577
2012-07-18T00:00:00Z